European Psychiatry - Volume 41 - April 2017

193 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237 S189
Results The SRS-P has shown good reliability (˛= .87) and
validity in relation to depressive symptoms (r= .67; P = .001),
anxiety (r= .74; P < .001), stress (r = .59; P = .004), inadequate
self (r = .43; P = .046), hated self (r = .54; P = .009), reassured
self (r= –.65; P = .001), self-compassion (r = –.63; P = .002), shame
(r = .46; P= .033) and empowerment regarding positive symptoms
(r = –.54; P = .015).
Conclusions The SRS-P presented adequate reliability and
convergent-divergent validity. Further studies are planned in order
to test the factorial structure of the scale and confirm the presented
results in a larger sample.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0244
Internal and external responsiveness
of the personal and social
performance scale in patients with
schizophrenia
E.C. Chiu ∗, C.L. Hsieh
1 National Taipei University of Nursing and Health Sciences,
Department of Long-Term Care, Taipei city, Taiwan, ROC
2 National Taiwan University, School of Occupational Therapy, Taipei
city, Taiwan, ROC
∗ Corresponding author.
Introduction The Personal and Social Performance scale (PSP) is
widely used to assess social functioningwith 4-domain scores and a
global score in patients with schizophrenia. However, internal and
external responsiveness of the PSP is largely unknown limiting its
use as an outcome measure.
Objectives The purpose of this study was to examine internal and
external responsiveness of the PSP in inpatients with schizophrenia
receiving treatments in the acute phase.
Methods Eighty patients were conducted the PSP and the Clinical
Global Impression-Severity (CGI-S) at admission and at discharge.
The standardized effect size (ES), the standardized response mean
(SRM), and paired t-test were used for examining internal respon-
siveness. We estimated correlations between the changes in scores
of the PSP and those of the CGI-S using Pearson’s r for investigated
external responsiveness.
Results For internal responsiveness, the ESs and the SRMs of the
domains were 0.74–1.74 and 0.68–1.72, respectively. The values
of the ES and the SRM in the global score were 1.72 and 1.74,
respectively. The paired t-tests showed statistically significant dif-
ference (P < 0.001) for the score changes of the four domains and the
global score. Regarding external responsiveness, fair and moderate
to good correlations (r= 0.35–0.74) were found among the changes
in the 4-domain scores and the global score with the those of the
CGI-S.
Conclusions The PSP has sufficient internal responsiveness and
substantial external responsiveness in inpatients with schizophre-
nia receiving treatments at the acute wards. The PSP is useful as an
outcome measure for detecting changes of social functioning over
time.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0245
Cognitive outcomes of Bergamot
Polyphenolic Fraction (BPF)
supplementation in schizophrenia:
Preliminary data
M. Crucitti∗, A. Bruno , G. Pandolfo , G.M. Troili , R.A. Zoccali ,
M.R.A. Muscatello
University of Messina, Department of Biomedical and Dental Sciences
and Morphofunctional Imaging, Messina, Italy
∗ Corresponding author.
Background Cognitive deficits in schizophrenia significantly
affect illness and community outcomes, and quality of life. Sev-
eral studies support the neuroprotective properties of polyphenolic
compounds resulting in neuronal protection, suppression of neu-
roinflammation and the potential to promote memory, learning
and cognitive functions. Bergamot differs from other citrus fruits
for flavonoids and flavonoid glycosides composition (neoeriocitrin,
neohesperidin, naringin, rutin, neodesmina, roifolina and ponci-
rina), and for their high amount. For these features, BPF may
represent a potential supplement for improving cognitive func-
tions.
Aims The present study was aimed to explore the efficacy of BPF
supplementation on clinical symptoms andcognitive functioning
in a sample of schizophrenic subjects receiving atypical antipsy-
chotics (APs).
Methods Ten schizophrenic outpatients treatedwith atypical APs
assumed BPF at the oral daily dose of 1000mg/day for 30 days.
Brief Psychiatric Rating Scale, Wisconsin Card Sorting Test, Verbal
Fluency Task-Controlled Oral Word Association Test, and Stroop
Color-Word Test were administered.
Results The results obtained indicate that BPF administra-
tion substantially improved WCST performances (perseverative
responses, P = 0.008; perseverative errors, P = 0.012; total errors,
P = 0.011; categories, P = 0.023). Moreover, a trend for others clini-
cal (BPRS) and cognitive variables (Verbal Fluency Task-Controlled
Oral Word Association Test, and Stroop Color-Word Test) decrease
was observed.
Conclusions The findings provide evidence that BPF adminis-
tration may be proposed as an effective therapeutic strategy to
improve cognitive outcome in schizophrenia. Further clinical tri-
als with adequately powered and well-designed methodology are
needed to better explore the BPF effectiveness on cognitive impair-
ments in schizophrenic patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0246
Neuropsychological profile of patients
in the first episode of psychosis
V.P. Bozikas ∗, A. Dardagani , P. Athanasis , I. Gliatas , E. Ntouros ,
E. Parlapani
Aristotle University of Thessaloniki, 1st Psychiatric Clinic- GH
Papageorgiou, Thessaloniki, Greece
∗ Corresponding author.
Neurocognitive dysfunction in patients presenting psychotic symp-
toms for the first time has been repeatedly noted by researchers.
However, there is still much diversity in data concerning the per-
formance of these patients in specific cognitive domains and their
degree of impairment. We used the Cambridge Neuropsychological
Test Automated Battery (CANTAB), in order to administer a com-
prehensive battery of neuropsychological tests. A series of tests
was selected measuring attention, memory, planning, inhibition,
shifting ability, mental flexibility, working memory and visuospa-
tial ability. The sample comprised 64 patients (37 male) with first
episode of psychosis and 14 healthy individuals (9 male). Patients’
performance was lower in all cognitive domains, in relation to the
performance of controls. More specifically, impairments in sus-
tained attention (–.6 SD), memory (–.7 SD), planning (–.6 SD),
working memory (–.7 SD), shifting ability (–.6 SD) and visuospatial
ability (–.6 SD) were prominent. Also, patients presented a severe
deficit in speed of processing (–.7 SD) and selective attention (–.6